Telescope Innovations Wins New Deal For Self-Driving Labs

A publicly traded company in Canada is leveraging artificial intelligence and robotics for the pharmaceutical business. And now, they’ve just landed a new major deal.

What’s happening:

• Telescope Innovations (CSE: TELI) has won a new deal with a major global pharmaceutical company to deploy their Self-Driving Labs in Europe
  

Why it matters:‍

• Telescope Innovations’ Self-Driving Labs are purpose built to autonomously execute chemistry experiments through leveraging robotic automation, advanced process analytics and artificial intelligence
  

Going deeper:‍

• Telescope Innovations has publicly stated the deployment of their Self-Driving Labs in Europe will be specifically tailored to crystallization which is one of the most traditionally time intensive stages of new drug development due to the need to control crystal forms, particle size and purity to ensure the drug substance is stable and bioavailable
  
• This is the third global pharmaceutical customer that Telescope Innovations has partnered with, previously striking deals with the Korean Pharmaceutical and Biopharma Manufacturers Association and Pfizer (NYSE: PFE)

‍